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Abstract
Background
Single-dose nevirapine (sd-NVP) has been the main option for prevention of mother-to-child
transmission (PMTCT) of HIV-1 in low-resource settings. However, sd-NVP can induce the
selection of HIV-1 resistant mutations in mothers and infants. In Mozambique, there are lim-
ited data regarding the profile of NVP resistance associated mutations (RAM) in the context
of PMTCT.
Objectives
To assess the prevalence and the factors associated with NVP RAM among children born
to HIV-1 infected mothers enrolled in the PMTCT programme adopted in Mozambique.
Methods
One hundred and fifty seven children aged 6 to 48 weeks were sequentially included (July
2011 to March 2012) at four centres in Maputo. Genotyping of RAM was performed in sam-
ples with HIV-1 RNA 100 copies/μL (Viroseq). Sequencing was performed with ABI 3100
(Applied Biosystems). Logistic regression modelling was undertaken to identify the factors
associated with NVP RAM.
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Results
Seventy-nine children had their samples genotyped. Their median age was 7.0 (3–12)
months and 92.4% received prophylaxis with sd-NVP at birth plus daily NVP. 35.4% of
mothers received antiretrovirals (ARVs) for PMTCT. ARV RAM were detected in 43 (54.4%)
of the children. 45.6% of these children had at least one NVP RAM. The most common
mutations associated with NVP resistance were K103N (n = 16) and Y181C (n = 15). NVP
RAM was significantly associated with mother exposure to PMTCT (crude odds ratio [OR]
30.3, 95% CI 4.93–186.34) and with mother’s CD4 count < 350 cells/mm3 (crude OR 3.08,
95% CI 1.02–9.32). In the multivariable analysis the mother’s exposure to PMTCT was the
only variable significantly associated with NVP RAM (adjusted OR 48.65, 95% CI 9.33–
253.66).
Conclusions
We found a high prevalence of NVP RAM among children who were exposed to the drug
regimen for PMTCT in Mozambique. The mothers’ exposure to PMTCT significantly
increased the risk of NVP RAM.
Introduction
In 2010, an estimated 390 000 children were newly infected with HIV, primarily due to
mother-to-child transmission (MTCT) [1]. Vertical transmission, which can occur during
pregnancy, labour, delivery or breastfeeding, remains the main mode of HIV infection in chil-
dren [2]. The implementation of preventive health policies such as pregnancy monitoring and
the administration of antiretroviral therapies (ART) led to a marked reduction in MTCT rates
in high-income countries [3]. However, in limited-resource settings, where full access to ART
has not been achieved, MTCT rates remain relatively high [4].
Two of the strategic goals of ‘The Global Plan towards the elimination of new HIV infec-
tions among children by 2015 and keeping their mothers alive’ are to achieve an ART coverage
among pregnant women of 90% and to reduce MTCT to rates< 5%, in low- or medium-
income countries with high estimated prevalence of pregnant women living with HIV [5]. In
2012, the coverage of ART programmes for prevention of MTCT (PMTCT) reached 65%
(range: 57 to 70%), among the sub-Saharan African countries [4].
Mozambique is one of the nine countries in sub-Saharan Africa with a prevalence of HIV
infection above 10% [6]. In 2009, the coverage of ART in the capital city of Maputo reached
77%. The PMTCT of HIV is a priority to the Mozambican Government, which has imple-
mented a national scale up plan towards the elimination of MTCT up to 2015. However, chil-
dren’s access to PMTCT programmes in Mozambique is still limited (~59%) [7].
Single-dose nevirapine (sd-NVP), a non-nucleoside reverse transcriptase inhibitor
(NNRTI), was adopted by several African countries in the PMTCT due to its good efficacy, low
cost, ease of administration and long plasma half-life [8–10]. However, sd-NVP can induce the
selection of HIV-1 resistant mutations in mothers and infants. A recent meta-analysis provided
a pooled estimate of NVP resistance prevalence of 35.7% and 52.6% in women and children
who used sd-NVP, respectively [11]. Some authors suggest that NVP-induced resistance after
exposure to MTCT prophylactic programmes may limit virological response to subsequent use
of NNRTIs in mothers and infants [3, 12, 13].
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The prophylactic regimen adopted by Mozambique follows the Option A preconized by the
World Health Organization (WHO) 2009 Guidelines [14]. In infants, this option consist of sd-
NVP at birth plus NVP prophylaxis up to the end of breastfeeding. Mothers receive zidovudine
(AZT) antepartum, sd-NVP at the onset of labour and twice daily AZT + lamivudine (3TC) for
7 days postpartum (sd-NVP and AZT + 3TC can be omitted if AZT antepartum did not exceed
4 weeks). Surveys conducted in Maputo in 2007 and 2009 revealed rates of transmitted drug
resistance to all ART classes below 5% [15].
Thus far, there is limited knowledge regarding the prevalence of NVP viral resistance muta-
tions in children born to HIV-1-infected mothers and who were exposed to maternal or child
programs of PMTCT in Mozambique. This knowledge is essential to tailor ARV strategies in
this population and maximize the effectiveness of ARV regimens in preventing MTCT.
In our work, we estimated the prevalence of viral resistance to NVP among children
exposed to the PMTCT programme adopted in Mozambique. We also explored the most
important factors associated with NVP resistance.
Methods
Setting and population
This cross-sectional study was carried out between July 2011 and March 2012. Children aged 6
to 48 weeks included in the Mozambican PMTCT program and born to HIV-1 infected moth-
ers were sequentially enrolled in the study according to their scheduled appointment at four
paediatric HIV centres in Maputo’s region. The study included mothers who needed ART to
treat their own health or mothers who just needed ARVs to reduce the risk of MTCT of HIV.
The PMTCT protocol followed in Mozambique at the time of this study was based onWHO
Rapid Advice—Use of antiretroviral drugs for treating pregnant women and preventing HIV
infection in infants–version 2 [14]. HIV-1 infected pregnant women who were eligible for ART
(primarily through CD4 screening) started this treatment, irrespective of the gestational age,
and continued throughout pregnancy, delivery and thereafter. The first-line ART regimen
included AZT + 3TC + NVP. The maternal ARV prophylaxis consisted of antepartum daily
AZT as early as 14 weeks of gestation, sd-NVP at onset of labour and twice daily AZT + 3TC
for 7 days postpartum.
The prophylaxis in breastfeeding children consisted of sd-NVP at birth and then daily
administration of NVP until one week after all exposure to breast milk ended. Non-breastfeed-
ing children received sd-NVP at birth and then daily administration of NVP or AZT until 4 to
6 weeks of age. HIV-infected infants received one of the following ART regimens: AZT or d4T
(stavudine) + 3TC + NVP or AZT or d4T + 3TC + LPV/r (lopinavir/ritonavir). Children with-
out CD4 count available and that had received ART out of the PMTCT programme were
excluded from the study.
Written informed consent was obtained from all children’s parents or legal guardians.
The study was approved by Mozambique’s National Health Bioethics Committee and by
the Mozambican Ministry of Health.
Data and specimen collection
Socio-demographic and clinical data were obtained from existing medical records. The
mother-related data included the WHO clinical stage of disease, type of PMTCT approach
(ART or prophylaxis), prophylactic scheme and duration of exposure to ARVs. The mother’s
viral load was not assessed at the time of labour (is not routine practice). The child-related vari-
ables were gender, age, delivery mode, birth weight, feeding practice, CD4 count, prophylactic
regimen and HIV-1 RNA levels.
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Two samples of peripheral blood (5 ml each) were collected from each child by venipunc-
ture. One sample was used for routine analysis and the other was shipped within 5 hours to the
Immunology Laboratory of Health National Institute in Mozambique. There, 200 μL were used
to determine the CD4 count by flow cytometry using FACSCalibur (Becton-Dickinson, San
Jose, California, USA); the remaining sample was centrifuged, plasma was isolated and stored
at -80°C. This sample was shipped to Hospital Egas Moniz in Lisbon within 12 months after its
collection, for genotyping of HIV-1 RNA and detection of ARV resistance associated muta-
tions (RAM). The shipment was performed in leak-proof containers specific for frozen samples
and containing dry ice. Temperature was checked at arrival to laboratory and no anomalies
were detected. HIV-1 RNA genotyping was performed by means of a commercially available
kit (ViroSeq HIV-1 genotyping system; Celera Diagnostics/Abbott Molecular Diagnostics,
Rome, Italy) based on RNA extraction, retrotranscription, DNA amplification, and sequencing
by an automated sequencer (ABI 3100; Applied Biosystems, Foster City, CA) [16].
Genotyping of ARV RAM was only carried out in samples with HIV-1 RNA levels 100
copies/μL, using the Stanford Resistance Database (HIVdb version 6.05) [17].
A NVP RAM was considered if at least one of the following genetic changes in reverse tran-
scriptase was detected: A98G, K101E, K101H, K101P, K103N, V106A, V106M, V108I, Y181C,
Y181V, Y188L and G190A.
HIV subtypes were determined by phylogenetic analysis of pol region sequences, using the
Rega Subtyping Tool v 2.0 [18].
Statistical Analysis
The sample size was calculated based on the population of Maputo, 1.209.993 persons, and a
rate of transmission of HIV drug resistance for all relevant ARVs and ARV classes of 4.0%,
observed in Malawi [19], a neighbouring country of Mozambique with similar characteristics
(low income, high illiteracy rates, poor sanitation and high rate of sexual activity). A sample of
120 children allowed the estimation of prevalence of NVP RAM with a 95% confidence interval
(CI) and a margin of error of 3.5%. Overall, 157 children were enrolled to account for specimen
losses above 20%.
Quantitative variables were summarised as median, minimum and maximum and qualita-
tive variables were summarised as absolute frequency. CIs were computed for the most preva-
lent mutations (> 5 cases). Odds ratio (OR) and 95%CI were used to explore the association
between independent variables and NVP RAM.
The bivariable analysis was conducted for all mother and child characteristics potentially
associated with NVP RAM. All variables with a p value 0.20 in the bivariable analysis, as well
as child’s gender and age, were included in the multivariable logistic regression analysis.
Adjusted ORs and 95% CIs were estimated for all independent predictors in the final selected
logistic model. All P values were two-sided and the level of significance was set at p<0.05.
Statistical analysis was performed using the Statistical Package for the Social Sciences, ver-
sion 19.0 (SPSS Inc., Chicago, IL, USA).
Results
General characteristics of the eligible population
Overall, 157 children met the eligibility criteria. The median age of the children was 7.0 months
(1–12 months) and 90 (57.3%) were male. Most children (75.8%; 119 of 157) had CD4 percent-
age>20%. Seventy-one per cent of mothers (111 of 157) were clinical stage 3 of HIV infection
and 127 (80.9%) were receiving ART.
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Seventy-nine of the 157 children (50.3%) had their sample sequenced for genotypic resis-
tance. The reasons for not performing resistance tests were the absence of HIV-1 RNA results
(n = 22) and undetectable HIV-1 RNA levels< 50 copies/μL (n = 56).
Table 1 summarises the characteristics of children with resistance test results as well as the
mothers’ variables of interest. The median age of children was 7 months (3–12 months) and 49
of 79 (62.0%) were male. The vast majority of children (87.3%; 69 of 79) were breastfed and CD4
percentage was> 20% in 48 of 79 children (60.8%). ARV prophylaxis consisted of sd-NVP at
birth plus daily NVP in 92.4% of the children. Almost all the children had HIV subtype C, 93.6%
(74 of 79). The remaining subtypes were A/C, A/D, C/B, C/D and B (data not shown).
No statistically significant differences were found for any of the variables of interest between
the 79 children who had the samples sequenced and the 78 children who did not.
Table 1. Mother and child socio-demographic and clinical characteristics among the population with
resistance test results.
Children (n = 79)
Age (months) 7.0 3–12
Male 49 62.0%
Delivery mode
vaginal 66 83.5%
caeserian 13 16.5%
Birth weight
 2.500 g 43 54.4%
< 2.500 g 36 45.6%
Feeding practice
formula feeding 10 12.7%
exclusive breastfeeding 69 87.3%
CD4 percentage 25.00 2–55%
<10% 10 12.7%
10–20% 21 26.6%
>20% 48 60.8%
ARV prophylaxis
AZT 6 7.6%
sd-NVP + daily NVP 73 92.4%
Mother (n = 79)
Clinical stage of HIV infection (WHO)
1 and 2 13 16.5%
3 and 4 66 83.5%
MTCT approach†
ART 51 64.6%
Prophylaxis 28 35.4%
Duration of exposure to ARVs (months) 8.00 0–38
CD4 count (cells/mm3) 540.00 108–1120
Data are number (%), median (range).
AZT, zidovudine; sd-NVP, single-dose nevirapine; MTCT, mother-to-child transmission; ARVs,
antiretrovirals; ART, antiretroviral therapy; mm3, cubic millilitre.
†The mother’s ﬁrst-line ART regimen included AZT + 3TC + NVP. The maternal ARV prophylaxis consisted
of antepartum daily AZT as early as 14 weeks of gestation, sd-NVP at onset of labour and twice daily
AZT + 3TC for 7 days postpartum.
doi:10.1371/journal.pone.0131994.t001
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The mothers were predominantly clinical stage 3 or 4 (83.5%; 66 of 79), 28 (35.4%) received
daily AZT as early at 14 weeks of gestation, sd-NVP at onset of labour and twice daily AZT +
3TC for 7 days postpartum, and 51 (64.6%) were on first-line ART regimen. The median dura-
tion of mother’s exposure to ARVs was 8 months (0–38 months) (Table 1).
NVP resistance associated mutations (RAM)
ARV RAM were detected in 43 of the 79 samples that were sequenced (54.4%; 95% CI 43.5–
65.4). Thirty-six samples (45.6%; 95% CI 34.6–56.6) had at least one NNTRI RAM, 33 samples
(41.8%; 95% CI 30.9–52.65) had NRTI RAM and seven samples (8.9%; 95% CI 2.6–15.1) had
PI RAM.
Overall, 74 NNTRI RAM, 54 NRTI RAM and eight PI RAM were observed. The NNRTI
RAMmost frequently represented in this ARV class were K103N (n = 16, 21.6%, 95% CI 12.2–
31.0) and Y181C (n = 15, 20.3%, 95% CI 11.1–29.4) and G190A (n = 10, 13.5%, 95% CI 5.7–
21.3). M184V (n = 27, 50.0%, 95% CI 36.7–63.3), T69N and D67N (n = 4, 7.4%) were the most
common NRTI RAM among this therapeutic class. PI resistance mutations were M46I (n = 5,
62.5%) and Q58E (n = 1, 12.5%), L90M (n = 2, 25.0%) (Fig 1).
All the samples with NNRTI RAM had at least one NVP RAM. Overall, 66 NVP RAM were
found. Of these, the most frequent mutations were K103N (n = 16, 24.2%, 95% CI 13.4–34.6)
and Y181C (n = 15, 22.7%, 95% CI 12.6–32.8), and G190A (n = 10, 15.2%, 95% CI 6.5–23.8).
There were also multiple occurrences of V108I (n = 6), A98G (n = 6), K101E (n = 4), V106A
(n = 4), K101P (n = 1). The mutations K101H, V106M, Y181V and Y188L were found in only
one sample each (Fig 2).
Factors associated with genotypic resistance to NVP
In the bivariable analysis, NVP RAM was significantly associated with mother’s exposure to
prophylaxis ARV (crude OR 30.3, 95% CI 4.93–186.34, P<0.0001) and with mother’s CD4
count<350 cells/mm3 (crude OR 3.08, 95% CI 1.02–9.32, P<0.04). No statistically significant
association was found between NVP RAM and child-related variables, mother HIV clinical
Fig 1. Profile of drug resistance associatedmutations by ARV class. Percentages were calculated based on the total number of RAM found for each
ARV class (NNTRI = 74, NRTI = 54 and PI = 8).
doi:10.1371/journal.pone.0131994.g001
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stage and duration of mother’s exposure to ART (Table 2). In the multivariable optimization
logistic regression, the mother’s exposure to prophylaxis ARV was the only variable that
remained significantly associated with NVP RAM (adjusted OR 48.65, 95% CI 9.33–253.66,
P<0.001). See S1 Table. Study Dataset.
Discussion
Our study aimed to estimate the prevalence of NVP RAM in children born to HIV-1 infected
mothers and who were exposed to the PMTCT programme preconized in Mozambique. The
prevalence of NVP RAM found in our sample was approximately 46%. This rate is within the
broad range of prevalence rates of NVP RAM found among several sub-Saharan African coun-
tries, which varies from 27%, in South Africa, to 76% in Malawi [20–22]. In 2010, a prospective
study with 740 Mozambican children who had received sd-NVP prophylaxis revealed a high
rate of NVP resistance (87%) among the group with established in utero infection and a rate of
38% when infection occurred in the peripartum period [23].
Of notice, almost all of the children had subtype C HIV infection. This finding is in line
with rates previously observed in Mozambique. Several studies showed that both women and
infants with subtype C HIV are more likely to develop NVP resistance after exposure to sd-
NVP than those infected with other HIV subtypes [24, 25].
We found that the mothers who took AZT and/or sd-NVP to provide MTCT prophylaxis
to their infant, instead of combination ART and with a low CD4 count had a statistically signif-
icant association with NVP RAM in the bivariable analysis. Children whose mothers had CD4
count< 350 cells/mm3, had a higher risk of NVP resistance than those children whose mothers
Fig 2. Profile of NVP resistance associated mutations (RAM). Percentages were calculated based on the total number of NVP RAM (n = 66). K103N and
Y181C were the most frequent NVP RAM (24.2% and 22.7% of the samples, respectively).
doi:10.1371/journal.pone.0131994.g002
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had CD4 count 350 cells/mm3 (OR = 3.08). The low CD4 count observed in mothers could
be attributable to virological failure and selection of resistance, which, in turn, could be trans-
mitted to the child. The majority of mothers in our sample (84%) were clinical stage 3 or 4 of
HIV infection.
In the multivariable logistic model the mothers that took antiretrovirals to prophylaxis their
fetus/infant significantly increased risk of NVP resistance (OR = 48.65) among children
Table 2. Logistic regression predicting NVP RAM adjusted for independent variables of interest.
NVP RAM
(n = 36)
Without NVP
RAM (n = 43)
Crude OR (95%
CI)
P-value Adjusted OR (95%
CI)*
P-
value
Child gender
Female 12 40.0% 18 60.0% reference
Male 24 48.0% 25 51.0% 1.44 (0.57–3.65) 0.4396 0.88 (0.25–3.12) 0.853
Child age (months)
< 6 9 36.0% 16 64.0% reference
6–12 27 50.0% 27 50.0% 1.78 (0.66–4.79) 0.2482 1.85 (0.50–6.87) 0.356
mean age ± SD 7.80 ± 2.89 6.67 ± 2.58 0.061
Delivery mode
Vaginal 7 53.9% 6 46.2% reference
Caeserian 29 43.9% 37 56.1% 0.67 (0.20–2.24) 0.5148
Birth weight (g)
< 2500 18 50.0% 18 50.0% 1.39 (0.57–3.42) 0.4690
 2500 18 41.9% 25 58.1% reference
Feeding practice
Exclusive breastfeeding 33 47.8% 36 52.2% reference
Infant formula 3 30.0% 7 70.0% 0.47 (0.11–2.00) 0.2932
Prophylaxis with NVP in children 32 45.7% 40 57.1% 0.60 (0.12–2.92) 0.5222
Mother exposure to ARV
ART 11 21.6% 40 78.4% reference
MTCT Prophylaxis 25 89.3% 3 10.7% 30.3 (4.93–
186.34)
<0.0001 48.65 (9.33–253.66) <0.001
Mother CD4 count (cells/mm3)
< 350 12 66.7% 6 33.3% 3.08 (1.02–9.32) 0.0408 1.75 (0.37–8.26) 0.477
 350 24 39.3% 37 60.7% reference
mean CD4 count 504.44 ± 283.14 619.23 ± 214.18 0.043
Duration of mother’s exposure to ARVs
(months)
0.31 (0.08–1.31) 0.111
< 12 8 33.3% 16 66.7% reference
 12 28 50.9% 27 49.1% 2.07 (0.75–5.75) 0.1517
Mother WHO staging of HIV infection
1 and 2 6 46.2% 7 53.9% reference
3 and 4 30 45.5% 36 54.6% 0.97 (0.29–3.23) 0.9633
Data are number (%); mean (standard deviation).
* The following independent variables were included in the multiple logistic adjusted regression analysis: child gender, child age, mother exposure to
ARV, mother CD4 count, maternal duration of exposure to ARVs.
Values in bold denote statistical signiﬁcance.
ART, antiretroviral therapy; CI, Conﬁdence Interval; OR, Odds Ratio; NVP RAM, nevirapine resistance associated mutations; MTCT, mother-to-child-
transmission; mm3, cubic millilitre.
doi:10.1371/journal.pone.0131994.t002
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comparing to mothers who received ART. This finding corroborates the results observed in
Maputo by Vaz et al [26], substantiating the evidence that sd-NVP-based prophylactic regi-
mens lead to a marked increase in the risk of resistance to this ARV and to the subsequent use
of NNRTIs [3, 12, 27, 28].
In our study, the risk of viral resistance to NVP was numerically higher among children
whose mothers were exposed to ARVs for more than 12 months but this finding had no statis-
tical significance (OR = 2.07).
In our sample, a high proportion of children (87.3%) were breastfed. An analysis of breast
milk samples from mothers of city of Beira in Mozambique who were exposed to sd-NVP,
showed a persistence of NVP-resistant HIV-1 up to 8 months postpartum [29]. Around 48% of
the children in our study that were breastfed had NVP resistance, which is above the rate of
NVP resistance detected in Beira, Mozambique (37.5%) [30] and below the rate found in
Malawi (66%) [21]. In the bivariable analysis we found no statistically significant association
between breastfeeding and an increased risk of NVP RAM.
Thirty-six of the 79 children that were successfully genotyped in our study exhibited at least
one mutation conferring resistance to NNRTIs. The most frequent reverse transcriptase muta-
tions were Y181C, K103N and G190A. Similar resistance patterns have been found in other
studies [31–33]. PI RAM were detected in a small sample of children, which reflects the low use
of PI in this population.
Limitations
The fact that we did not know the mothers ART history and their ARV resistance profile con-
stitutes one major limitation of our study. As a result, we could not discriminate between resis-
tance mutations that were due to ART or PMTCT and the ones that were selected in the child.
WHO endorses the regular surveillance of ARV resistant HIV in patients who receive ART for
the first time. Several studies conducted in sub-Saharan African countries found rates of pri-
mary resistance around 5% [34]. Furthermore, we were unable to identify if mothers were pre-
viously exposed to NVP-containing regimens and, therefore, assess the impact of this potential
confounder of NVP resistance development.
We have not investigated the persistence of detectable NVP resistance in our sample. Evi-
dence shows that children’s exposure to sd-NVP is associated with NVP-resistant mutations
that can persist for a year or more [35–37]. This persistence seems to be more marked after
exposure to extended NVP prophylaxis [38, 39]. Among HIV-infected Ugandan infants with
NVP resistance at 6 weeks of age, NVP-resistant HIV variants were still detected at 6 months
in all seven infants who received the extended NVP regimen, compared to only one of six
infants who received sd-NVP alone [38].
A larger sample would have provided more robust findings regarding the outcomes of inter-
est. Some of the specimens were not sequenced due to poor quality or delay in its shipment.
Moreover, the available sequencing assays were not able to detect resistance for samples with
HIV RNA levels< 100 copies/μL.
With the rapid scale up of ART in Mozambique, more than 16.000 children have been
exposed to ARVs up to 2011. Despite gradually improving access to ART, the proportion of
children currently treated in the country is considerably small. As of December 2010 only 23%
of HIV-infected children aged< 15 years old in need of ART were receiving this therapy [26,
33].
The identification of the factors most associated with virological response and prevention of
resistance to ARVs is crucial for an appropriate management of ART programmes, the optimi-
zation of the use of resources and a better definition of treatment strategies. This knowledge is
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especially relevant in low-income settings, where state of the art techniques such genotyping
systems are not widely available.
Recent findings showed that the use of ART including ritonavir-boosted protease inhibitors
(PI/r) in PMTCT is more effective than regimens containing one NNRTI [28, 40]. This evi-
dence led to the update of the recommendations followed in Mozambique, which now endorse
the use of an ARV regimen that includes PI/r. This measure, accompanied by all the intensive
efforts aiming to eliminate AIDS in the paediatric population, may lead to improved outcomes
in the PMTCT of HIV.
Conclusions
This study revealed a high prevalence of NVP resistance associated mutations among children
born to HIV-1 infected mothers and who were exposed to the PMTCT programme in Mozam-
bique. In addition, the mothers’ exposure to PMTCT regimen significantly increased the risk
of NVP resistance mutations.
Systematic surveillance of ARV associated resistance mutations should be a priority in
Mozambique. It is essential to implement and disseminate new recommendations for the
PMTCT, which should endorse the introduction of ART to all HIV-infected pregnant women,
regardless of CD4 count or the treatment of infected children. The ARV regimens should
include one PI/r and should be permanently available in all healthcare units that manage this
condition. This is the only way to reduce the incidence of AIDS in this country and improve
the survival rates of children living with HIV.
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